Femara Granted FDA Priority Review for New Indication as Adjuvant Treatment for Postmenopausal Women with Early Breast Cancer
5th Sep 2005, 11:57 GMT
Enhanced efficacy in subgroups at potentially higher risk for breast cancer recurrence in which existing therapies have not demonstrated benefit